Analysts expect Xilio Therapeutics, Inc. to report revenue of 5.09 M for Q3 26, against a range of 4.78 M to 5.41 M. The most recent reported quarter, Q2 26, came in at 18.69 M, a 42.6% beat against the 13.11 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 2.28 M | 1.72 M | 2.92 M | 8.09 M | 19.07 M | 13.69 M | 12.65 M | 18.69 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 3.84 M | 3.24 M | 4.88 M | 8.44 M | 19.19 M | 11.62 M | 8.83 M | 14.07 M | 5.41 M | 4.36 M | 3.12 M | 19.04 M | 10.48 M | 7.29 M | -2.41 M | 7.89 M | ||||||||||
| Low Estimate | 3.19 M | 2.97 M | 4.29 M | 7.49 M | 16.85 M | 10.92 M | 7.57 M | 12.15 M | 4.78 M | 4.09 M | 2.60 M | 16.81 M | 9.33 M | 6.12 M | -2.68 M | 6.71 M | ||||||||||
| Consensus Estimate | 3.51 M | 3.11 M | 4.58 M | 7.97 M | 18.02 M | 11.27 M | 8.20 M | 13.11 M | 5.09 M | 4.22 M | 2.86 M | 17.92 M | 9.90 M | 6.71 M | -2.54 M | 7.30 M |
Analysts expect Xilio Therapeutics, Inc. to report earnings per share of -0.91 for Q3 26, against a range of -0.95 to -0.87. The most recent reported quarter, Q2 26, came in at -0.33, a 42.1% beat against the -0.57 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -3.08 | -2.80 | -2.52 | -2.24 | -1.54 | 0.81 | -0.58 | -0.33 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -3.37 | -2.88 | -2.66 | -1.01 | -0.40 | -0.98 | -0.67 | -0.53 | -0.87 | -0.85 | -0.85 | -0.28 | -0.33 | -0.10 | -1.18 | -0.74 | ||||||||||
| Low Estimate | -3.97 | -3.40 | -3.08 | -1.09 | -0.46 | -1.10 | -0.73 | -0.61 | -0.95 | -1.01 | -0.97 | -0.34 | -0.35 | -0.12 | -1.42 | -0.86 | ||||||||||
| Consensus Estimate | -3.67 | -3.14 | -2.87 | -1.05 | -0.43 | -1.04 | -0.70 | -0.57 | -0.91 | -0.93 | -0.91 | -0.31 | -0.34 | -0.11 | -1.30 | -0.80 |
Pull Wall Street consensus for Xilio Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=XLO&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "XLO", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=XLO&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();